BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11602410)

  • 21. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.
    De Vita S; Zaja F; Sacco S; De Candia A; Fanin R; Ferraccioli G
    Arthritis Rheum; 2002 Aug; 46(8):2029-33. PubMed ID: 12209504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.
    Zinzani PL; Tani M; Marchi E; Stefoni V; Alinari L; Musuraca G; Gabriele A; Pileri S; Baccarani M
    Haematologica; 2004 Mar; 89(3):309-13. PubMed ID: 15020269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hairy cell leukemia: a model for studying the B cell family of diseases.
    Al-Katib A; Berman E; Black P; Koziner B
    Semin Oncol; 1986 Dec; 13(4 Suppl 5):48-54. PubMed ID: 3492047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hairy-cell leukemia and alpha-interferon treatment: long-term responders.
    Zinzani PL; Lauria F; Salvucci M; Rondelli D; Raspadori D; Bendandi M; Magagnoli M; Tura S
    Haematologica; 1997; 82(2):152-5. PubMed ID: 9175317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.
    Younes A; Romaguera J; Hagemeister F; McLaughlin P; Rodriguez MA; Fiumara P; Goy A; Jeha S; Manning JT; Jones D; Abruzzo LV; Medeiros LJ
    Cancer; 2003 Jul; 98(2):310-4. PubMed ID: 12872350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody.
    Mourad YA; Taher A; Chehal A; Shamseddine A
    Ann Hematol; 2004 May; 83(5):319-21. PubMed ID: 15060751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
    Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
    Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients.
    Addeo R; Caraglia M; Costanzo R; Faiola V; Montella L; Abbruzzese A; Del Prete S
    Oncol Rep; 2004 Jul; 12(1):135-40. PubMed ID: 15201974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient.
    Pollio F; Pocali B; Palmieri S; Morabito P; Scalia G; Del Vecchio L; Ferrara F
    Ann Hematol; 2002 Dec; 81(12):736-8. PubMed ID: 12483372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
    Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
    Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
    Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
    Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
    Saleh MN; Gutheil J; Moore M; Bunch PW; Butler J; Kunkel L; Grillo-López AJ; LoBuglio AF
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):99-103. PubMed ID: 11226008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia.
    Damasio EE; Resegotti L; Masoudi B; Bruni R; Cerri R; Isaza A; Clavio M; Risso M; Rossi E; Spriano M; Truini M
    Recenti Prog Med; 1998 Feb; 89(2):68-73. PubMed ID: 9558908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant alpha-interferon (alpha-IFN) for progressive hairy-cell leukemia (HCL): a study in previously untreated nonsplenectomized patients.
    Schwarzinger I; Bettelheim P; Chott A; Herold C; Hinterberger W; Köller U; Kos M; Neumann E; Radaszkiewicz T; Lechner K
    Wien Klin Wochenschr; 1988 Jan; 100(2):47-51. PubMed ID: 3348041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
    Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
    Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dyserythropoietic changes and sideroblastic anemia in patients with hairy cell leukemia before and after therapy with 2-chlorodeoxyadenosine.
    Zák P; Chrobák L; Podzimek K; Plísková L; Dedic K
    Neoplasma; 1998; 45(4):261-5. PubMed ID: 9890671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia.
    Hagberg H; Lundholm L
    Br J Haematol; 2001 Dec; 115(3):609-11. PubMed ID: 11736943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.